# US 2023/0265079 A1 · Inhibitor of indoleamine 2,3-dioxygenase-1 and methods of manufacture and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265079 A1
- Document ID: US20230265079A1
- Status: Published application
- Kind: A1
- Application number: 18/096,397
- Filed: 2023-01-12
- Published: 2023-08-24
- Earliest claimed: 2018-01-10
- Assignees: University Health Network
- Applicants: University Health Network
- Inventors: Donald WEAVER; Michael G. BRANT; Stephanie WOHNIG; Fan WU; Jake GOODWIN-TINDALL; Autumn MEEK; Paolo SCHIAVINI
- Web page: https://patentgrep.com/patent/US20230265079A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 401/14: containing three or more hetero rings
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/14: containing three or more hetero rings
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Inhibition of indoleamine 2,3-dioxygenase (IDO1) is an attractive immunotherapeutic approach for the treatment of a variety of cancers. Dysregulation of this enzyme has also been implicated in other severe diseases such as Alzheimer's disease and arthritis. Small molecule inhibitors of IDO, syntheses, and uses thereof are provided.

## Claims

### Claim at position 1

1-7. (canceled)

### Claim 8

A method of treating a disease associated with tryptophan metabolism in a subject, the method comprising administering a therapeutically effective amount to a subject of a compound, or a pharmaceutically acceptable salt thereof, of either of Formulas I:
wherein
X is H, F, Cl, or Br;
R1 is piperidin-2-yl, 1-phenylmethan-1 -yl-1-ol, pyrrol-2-yl, or
and R2, R3, R4, R5, and R6 are each independently H, F, Cl, amino, hydroxy, alkoxy, cyano, trifluoromethyl, or phenyl.

### Claim 9 (depends on 8)

The method of claim 8 in which the disease is cancer.

### Claim 10 (depends on 9)

The method of claim 9 in which the disease is glioblastoma multiforme.

### Claim 11 (depends on 8)

The method of claim 8 in which the disease is neurodegeneration.

### Claim 12 (depends on 11)

The method of claim 11 in which the disease is Alzheimer's disease.

### Claim at position 7

13-19. (canceled)

### Claim 20 (depends on 8)

The method of claim 8, wherein R1 is

### Claim 21 (depends on 20)

The method of claim 20, wherein R4 is H, F, Cl, amino, hydroxy, alkoxy, cyano, trifluoromethyl, or phenyl; and R2, R3, R5, and R6 are each independently H, F, Cl, amino, or hydroxy.

### Claim 22 (depends on 21)

The method of claim 21, wherein R4 is H, F, Cl, amino, hydroxy, methoxy, or cyano.

### Claim 23 (depends on 22)

The method of claim 22, wherein the compound is of Formula Ia; X is Br; R4 is H, methoxy, or cyano; R2 is H, amino, or hydroxy; and R3, R5, and R6 are each H.

### Claim 24 (depends on 22)

The method of claim 22, wherein the compound is of Formula Ib; X is F or Br; R6 is H; R5 is H, F, or Cl; R3 and R4 are each H, Cl, or hydroxy; and R2 is H or hydroxy.

### Claim 25 (depends on 8)

The method of claim 8, wherein the compound is of Formula 1b, R1 is pyrrol-2-yl, and X is F or Br.
